Vivek Ra­maswamy re­cruits Eli Lil­ly R&D vet Salz­mann as new CEO; Ax­o­vant drops col­lab­o­ra­tion

→ Vivek Ra­maswamy has re­cruit­ed Eli Lil­ly R&D vet Pe­te Salz­mann to take the helm at one of his new vants. Salz­mann is the new CEO at Im­muno­vant, which is work­ing on IMVT-1401, a mon­o­clon­al an­ti­body in de­vel­op­ment for the treat­ment of au­toim­mune dis­eases me­di­at­ed by path­o­gen­ic IgG an­ti­bod­ies. Salz­mann had been in charge of the de­vel­op­ment pro­gram for Olu­mi­ant (baric­i­tinib), which proved trou­ble­some for Eli Lil­ly as reg­u­la­tors raised se­ri­ous con­cerns about safe­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER